McDermott is committed to providing insightful commentary on intellectual property (IP) developments from around the world to our Japanese clients. In light of that effort, we are pleased to announce that our free webinar...more
Under the University and Small Business Patent Procedures Act of 1980 (35 U.S.C. §§ 200-212), commonly referred to as the Bayh-Dole Act, the federal government can exercise “march-in” authority in certain circumstances to...more
1/11/2024
/ Bayh-Dole Act ,
Biden Administration ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Hatch-Waxman ,
Healthcare ,
Inventions ,
March-in-Rights ,
National Institute of Health (NIH) ,
NIST ,
Patent Ownership ,
Patents ,
Public Comment ,
Regulatory Agenda ,
Regulatory Reform ,
Request For Information
マクダーモット・インターナショナル・セミナーは、おかげさまで皆様よりご好評をいただき、11回目となるセミナーを東京で開催することが決定いたしました。
本セミナーでは、オースティン、ブリュッセル、ロンドン、ミュンヘン、パリ、サンフランシスコ、ワシントンD.C.の各オフィスの、ビジネス法務の第一線で活躍する経験豊富な弁護士が、日本の企業や法律事務所の皆様に向けて、米国・欧州における法律および実務の重要トピックスに関する最新動向をご提供いたします...more
1/8/2024
/ Antitrust Provisions ,
Artificial Intelligence ,
Best Practices ,
CFIUS ,
Competition ,
Continuing Legal Education ,
Cross-Border Transactions ,
Cybersecurity ,
Data Privacy ,
European Commission ,
Events ,
Foreign Direct Investment ,
Foreign Investment ,
Intellectual Property Protection ,
National Security ,
Supply Chain ,
UK Competition and Markets Authority (CMA)
McDermott is pleased to bring our Life Sciences Boot Camp for In-House Counsel back to the Bay Area!
Amid turbulent economic forces, life sciences companies continue to grapple with increasingly complex legal and business...more
3/21/2023
/ Acquisitions ,
Compliance ,
Continuing Legal Education ,
Corporate Counsel ,
Enforcement ,
Events ,
Food and Drug Administration (FDA) ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Life Sciences ,
Medical Devices ,
Mergers ,
NAD ,
Pharmaceutical Industry ,
Prescription Drugs
Patents / Patent Eligible Subject Matter -
Supreme Court to Myriad: Isolated DNA Sequences Are Not Patent-Eligible Subject Matter --
AMP et al. v. Myriad Genetics, Inc.:
In a 9–0 decision the Supreme...more
6/27/2013
/ Abuse of Discretion ,
AMP v Myriad ,
Burden of Proof ,
Copyright ,
Damages ,
DNA ,
False Advertising ,
First Amendment ,
Human Genes ,
Infringement ,
Lanham Act ,
Myriad ,
Oprah Winfrey ,
Patent Terms ,
Patent-Eligible Subject Matter ,
Patents ,
Permanent Injunctions ,
SCOTUS ,
Time Warner ,
Trade Secrets ,
Trademarks ,
USPTO ,
Willful Infringement
The Supreme Court of the United States has released its highly anticipated decision in AMP et al. v. Myriad Genetics, Inc., et al., on the patenting of genes. This On the Subject discusses the Supreme Court decision and the...more
6/17/2013